Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) EV/FCF
As of 5 November 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a EV/FCF of 60.7×. Over the past ten years it has ranged from −491× (July 2024) to 154× (October 2019); the current reading is higher than 91% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 56.2× | 183.84% |
| FY2024 | 19.8× | — |
| FY2023 | −302× | — |
| FY2022 | 8.8× | (66.16%) |
| FY2021 | 26.1× | 8.21% |
| FY2020 | 24.1× | — |
| FY2019 | −27.7× | — |
| FY2018 | 10.0× | (55.16%) |
| FY2017 | 22.2× | (43.23%) |
| FY2016 | 39.2× | 3.90% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 63.0× | 46.29% |
| Jun 2026 | 43.1× | 56.58% |
| Mar 2026 | 27.5× | (51.05%) |
| Dec 2025 | 56.2× | (55.51%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −79.2× |
| ORKA Oruka Therapeutics, Inc. compare | −51.4× |
| KOD Kodiak Sciences Inc. compare | −35.4× |
| CGON CG Oncology, Inc. compare | −26.2× |
| PTCT PTC Therapeutics, Inc. compare | −24.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −21.1× |
| IMVT Immunovant, Inc. compare | −12.2× |
| IONS Ionis Pharmaceuticals, Inc. compare | −10.9× |
| LGND Ligand Pharmaceuticals Incorporated | 60.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement